Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer
Micromet, Inc. announced the appointment of Jan Fagerberg, M.D., Ph.D., as Senior Vice President and Chief Medical Officer effective November 1, 2009.
Dr. Fagerberg is a board-certified clinical oncologist and has more than 20 years of experience in clinical research and development of oncology drugs. His experience includes several years at F. Hoffmann-La Roche in positions of increasing responsibility both in the US and in Switzerland, ultimately serving as the Therapeutic Area Expert Oncology in Global Drug Development of Hoffmann-La Roche in Basel, Switzerland. During his tenure at Roche, he was responsible for the global clinical development of Xeloda, and for the clinical development programs of Avastin outside the US. He was also advising Roche's clinical development teams globally on the development of all compounds for the treatment of gastrointestinal cancers. Dr. Fagerberg has extensive US and European regulatory experience, and was successful in obtaining 11 FDA and EMEA approvals for Xeloda and Avastin. Dr. Fagerberg joins Micromet from TopoTarget where he was Medical Director responsible for the pivotal clinical development program for belinostat for the treatment of peripheral T-cell lymphoma.
Dr. Fagerberg received his MD degree at the Karolinska Institute in Stockholm Sweden in 1988. He then received his Ph.D. for work in clinically applied passive and active immunotherapy targeting EpCAM in colorectal carcinomas in 1995. From 1995 to 1999 Jan held various clinical positions including Associate Head Section of Radiotherapy and Chief Physician at the Karolinska Hospital in Stockholm. Dr. Fagerberg joined Roche in 1999 and over the following seven years assumed positions of increasing responsibility. Since 2006 he has been Medical Director at TopoTarget in Copenhagen, Denmark.
Other news from the department people
